

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Date: 12th November, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Outcomes of Board Meeting and Un-Audited Financial Results for the quarter ended 30.09.2021 and year to date from 01.04.2021 to 30.09. 2021

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter ended 30.09.2021 and year to date from 01.04.2021 to 30.09. 2021

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 30.09.2021 and year to date from 01.04.2021 to 30.09.2021 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 12:40 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited

Yogesh Agrawal
Managing Director
DIN: 01165288
Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi – 110063


GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Statement of Un-Audited Financial Results for the quarter ended 30/09/2021 and Year to date from 01/04/2021 to 30/09/2021

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for corresponding period ended	Previous year ended
		30-Sep-21 Un-Audited	30-Jun-21 Un-Audited	30-Sep-20 Un-Audited	30-Sep-21 Un-Audited	30-Sep-20 Un-Audited	31-Mar-21 Audited
I	Revenue From Operations	289,800	169,600	669,690	459,400	947,290	2,080,805
II	Other Income	-	-	-	-	-	29,221
III	Total Revenue (I+II)	289,800	169,600	669,690	459,400	947,290	2,110,026
IV	Expenses						
	Cost of materials consumed	4000	-	8540	4,000	8,540	50,242
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	765,600	765,600
	Employee benefits expense	246,250	177,200	194,444	423,450	519,934	857,734
	Financial costs	-	426,203	-	426,203	-	1,774,570
	Depreciation and amortization expense	470,238	470,238	481,439	940,476	962,878	1,892,123
	Other expenses	140,967	183,714	248,963	324,681	308,842	1,787,900
	Total Expenses (IV)	861,455	1,257,355	933,386	2,118,810	2,565,794	7,128,169
V	Profit / (Loss) before exceptional item and tax (III-IV)	-571,655	-1,087,755	-263,696	-1,659,410	-1,618,504	-5,018,143
VI	Exceptional Item	-	-	-	-	-	-
VII	Profit/loss before Tax (V-VI)	-571,655	-1,087,755	-263,696	-1,659,410	-1,618,504	-5,018,143
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	572,371
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	-571,655	-1,087,755	-263,696	-1,659,410	-1,618,504	-5,590,514
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	-571,655	-1,087,755	-263,696	-1,659,410	-1,618,504	-5,590,514
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	-571,655	-1,087,755	-263,696	-1,659,410	-1,618,504	-5,590,514
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	-0.19	-0.36	-0.09	-0.54	-0.53	-1.83
	2) Diluted	-0.19	-0.36	-0.09	-0.54	-0.53	-1.83
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	-0.19	-0.36	-0.09	-0.54	-0.53	-1.83
	2) Diluted	-0.19	-0.36	-0.09	-0.54	-0.53	-1.83

K. G. Singh



GENOMIC VALLEY BIOTECH LIMITED


REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER, 2021

Particulars	Amount in INR		
	30.09.2021	30.09.2020	31.03.2021
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit As Statement Profit & Loss	-1,659,410	-1,618,504	-5,018,143
Adjustment For			-
Discount received	-	-	-
Non-Operating Income	-	-	-
Interest Income	-	-	151
Loss on sale of assets	-	-	-
Depreciation and Amortisation Expenses	940,476	962,878	1,892,123
Operating Profit Before Change in Working Capital	-718,934	-655,626	-3,125,869
ADJUSTMENTS FOR WORKING CAPITAL:			
Increase/Decrease in Loans and Advances	-	19,650,000	14,650,000
Increase/ Decrease in Inventories	-	765,600	1,239,623
Increase/Decrease in Security Deposits	-16,000,000	-	150,000
Increase/Decrease in Trade Receivables	-65,880	358,600	377,573
Increase/Decrease in Other Current Assets	-439,186	-357,346	527,707
Increase/Decrease in Current Liabilities	-5,433,218	-4,030,909	1,028,228
CASH GENERATED FROM OPERATIONS	-22,657,216	15,730,320	14,847,262
Taxes Paid			
Total (A)	-22,657,216	15,730,320	14,847,262
B. CASH FLOW FROM INVESTING ACTIVITIES			
Additions/Sales to fixed assets	49,166,000	-15,793,000	-15,793,000
Purchase/Sell of Investments	-	-	-
Discount received	-	-	-
Non-Operating Income	-	-	-
Interest Income	-	-	-151
Total (B)	49,166,000	-15,793,000	-15,793,151
C. CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from Borrowings	-26,545,944	-	682,867
Preliminary Expenses	-	-	-
Total (C)	-26,545,944	-	682,867
NET CASH FLOWS DURING THE YEAR (A+B+C)	-37,161	-62,680	-263,022
Cash and Cash Equivalents (Opening Balance)	114,532	377,554	377,554
Cash and Cash Equivalents (Closing Balance)	77,371	314,874	114,532

Kamran



Statement of Asset and Liabilities as at September 30, 2021

Particulars	Current half year ended	Previous year ended
	30/09/2021	31/03/2021
	Un-Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	8,480,763	58,587,239
Capital work in progress	4,879,339	4,879,339
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	10,950,000	10,950,000
Security Deposits	16,050,000	50,000
Other financial assets	-	-
Deferred tax assets (Net)	80,812	80,812
Other non current assets	-	-
Total Non-Current Assets	40,440,914	74,547,390
Current Assets		
Inventories	-	-
Financial Assets:	-	-
Investments	-	-
Trade Receivables	714,999	649,119
Cash and Cash equivalents	3,133	-
Other Balances with banks	74,238	114,532
Loans	-	-
Other financial assets	-	-
Other Current assets	1,311,839	872,654
Total Current Assets	2,104,209	1,636,305
Total Assets	42,545,123	76,183,694
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	30,545,000	30,545,000
Other Equity	2,175,235	14,334,645
Total Equity	32,720,235	44,879,645
Non Current Liabilities		
Financial liabilities		
Borrowings	-	15,470,944
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	-	-
Provisions	-	-
Other Non Current liabilities	6,545,000	7,120,000
Total Non Current Liabilities	6,545,000	22,590,944
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	543,180	395,220
Other Financials liabilities	-	-
Provisions	134,569	129,834
Other Current liabilities	2,602,138	8,188,051
Total Current Liabilities	3,279,887	8,713,105
TOTAL EQUITY AND LIABILITIES	42,545,123	76,183,694

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on November 12, 2021. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.

- 2 The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
- 3 Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- 4 Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



A handwritten signature in black ink, appearing to read "Yogesh Agrawal".

Yogesh Agrawal
(Managing Director)
DIN-01165288

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 12/11/2021

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended
September 30, 2021 and year to date from April 01, 2021 to September 30, 2021**

We have reviewed the accompanying statement of unaudited financial results for **the Quarter ended September 30, 2021 and year to date from April 01, 2021 to September 30, 2021** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.
Chartered Accountants



Place: Delhi
Date: 12-11-2021

Bhavuk Garg

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

UDIN: 21502310-AAAAQL-8698